Ozaki, H., Sasaki, N. and Kitajima, S.

An aminoacyl-tRNA synthetase governs dsRNA-mediated trade-off between longevity and innate immunity.
Mol. Cell, 86, 2237-2239 (2026)

Kamakura, N., Jo, M., Takahashi, M. and Hirota, T.

Targeting cell cycle vulnerabilities in cancers: Emerging strategies for therapeutic development.
Cancer Sci., in press (2026)

Tanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Higo, H., Rai, K., Ichihara, E., Tomida, S., Hotta, K., Togashi, Y., Maeda, Y., Kiura, K., Katayama, R. and Ohashi, K.

Afatinib overcomes osimertinib resistance via Egfr v804f mutation in a syngeneic Egfr-mutant lung cancer mouse model.
Cancer Sci., in press (2026)

Nagasaka, M., Facchinetti, F., Bigot, L., Brayé, F., Groves, M. R., Yosa, J., Wekken, A. V., Aldea, M., Besse, B., Planchard, D., Naltet, C., Katayama, R., Olaussen, K. A., Loriot, Y. and Friboulet, L.

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
npj Precis. Oncol., in press (2026)

Kurosaki, T., Suzuki, S., Watanabe, Y., Kenmotsu, H., Itoh, S., Yamaguchi, M., Shiono, A., Suzuki, T., Yokoyama, T., Toi, Y., Tanaka, H., Oki, M., Tsuda, T., Ichihara, E., Azuma, K., Tanaka, H., Arai, R., Uchibori, K., Miyauchi, E., Katayama, R. and Hayashi, H.

Immune-related gene expression profiling and alectinib efficacy for patients with ALK-rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Lung Cancer, 216, 109416 (2026)

more